Syndax Pharmaceuticals Inc (SNDX): Shareholders' Equity
$64.63M
As of 2025-12-31
$15.10M
As of 2026-06-30
-48.3%
3-year compound annual growth
-23.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.63M | -77.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $288.12M | -48.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $554.20M | +18.6% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $467.45M | +14.5% | 2025-03-03, Balance as of period end |
| 2021-12-31 | $408.37M | +61.9% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $252.19M | +698.1% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $31.60M | -40.4% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $53.05M | -49.1% | 2021-03-12, Balance as of period end |
| 2017-12-31 | $104.32M | +24.0% | 2020-03-05, Balance as of period end |
| 2016-12-31 | $84.14M | n/m | 2019-03-07, Balance as of period end |
| 2015-12-31 | -$252.41M | n/m | 2018-03-08, Balance as of period end |
| 2014-12-31 | -$152.57M | n/a | 2017-03-14, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $352.46M | +53.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $212.38M | -34.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $139.07M | +540.0% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗